EdgarLookup

GARMIN LTD — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that GARMIN LTD filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
23%
Profit Margin
Net income ÷ revenue
15.1%
Return on Assets
Net income ÷ assets
+15.1%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $7.25B Feb 18, 2026
FY2025 Dec 28, 2024 $6.30B Feb 18, 2026
FY2025 Dec 30, 2023 $5.23B Feb 18, 2026
FY2024 Dec 31, 2022 $4.86B Feb 19, 2025
FY2023 Dec 25, 2021 $4.98B Feb 21, 2024
FY2020 Dec 26, 2020 $1.35B Feb 17, 2021
FY2020 Sep 26, 2020 $1.11B Feb 17, 2021
FY2020 Jun 27, 2020 $869.87M Feb 17, 2021
FY2020 Mar 28, 2020 $856.11M Feb 17, 2021
FY2020 Dec 28, 2019 $1.10B Feb 17, 2021

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 30, 2017 $888.50M Feb 21, 2018
FY2017 Sep 30, 2017 $743.08M Feb 21, 2018
FY2017 Jul 1, 2017 $816.89M Feb 21, 2018
FY2017 Apr 1, 2017 $638.55M Feb 21, 2018
FY2017 Dec 31, 2016 $860.77M Feb 21, 2018
FY2017 Sep 24, 2016 $722.25M Feb 21, 2018
FY2017 Jun 25, 2016 $811.61M Feb 21, 2018
FY2017 Mar 26, 2016 $624.04M Feb 21, 2018
FY2016 Dec 26, 2015 $781.36M Feb 22, 2017
FY2016 Sep 26, 2015 $679.69M Feb 22, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $4.26B Feb 18, 2026
FY2025 Dec 28, 2024 $3.70B Feb 18, 2026
FY2025 Dec 30, 2023 $3.00B Feb 18, 2026
FY2024 Dec 31, 2022 $2.81B Feb 19, 2025
FY2023 Dec 25, 2021 $2.89B Feb 21, 2024
FY2020 Dec 26, 2020 $790.98M Feb 17, 2021
FY2020 Sep 26, 2020 $667.98M Feb 17, 2021
FY2020 Jun 27, 2020 $515.43M Feb 17, 2021
FY2020 Mar 28, 2020 $506.94M Feb 17, 2021
FY2020 Dec 28, 2019 $639.46M Feb 17, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.66B Feb 18, 2026
FY2025 Dec 28, 2024 $1.41B Feb 18, 2026
FY2025 Dec 30, 2023 $1.29B Feb 18, 2026
FY2024 Dec 31, 2022 $973.59M Feb 19, 2025
FY2023 Dec 25, 2021 $1.08B Feb 21, 2024
FY2020 Dec 26, 2020 $333.55M Feb 17, 2021
FY2020 Sep 26, 2020 $313.42M Feb 17, 2021
FY2020 Jun 27, 2020 $184.18M Feb 17, 2021
FY2020 Mar 28, 2020 $161.18M Feb 17, 2021
FY2020 Dec 28, 2019 $360.79M Feb 17, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.88B Feb 18, 2026
FY2025 Dec 28, 2024 $1.59B Feb 18, 2026
FY2025 Dec 30, 2023 $1.09B Feb 18, 2026
FY2024 Dec 31, 2022 $1.03B Feb 19, 2025
FY2023 Dec 25, 2021 $1.22B Feb 21, 2024
FY2022 Dec 26, 2020 $1.05B Feb 22, 2023
FY2021 Dec 28, 2019 $945.59M Feb 16, 2022
FY2020 Dec 29, 2018 $778.34M Feb 17, 2021
FY2019 Dec 30, 2017 $683.64M Feb 19, 2020
FY2018 Dec 31, 2016 $632.86M Feb 20, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.13B Feb 18, 2026
FY2025 Dec 28, 2024 $993.60M Feb 18, 2026
FY2025 Dec 30, 2023 $904.70M Feb 18, 2026
FY2024 Dec 31, 2022 $834.93M Feb 19, 2025
FY2023 Dec 25, 2021 $778.75M Feb 21, 2024
FY2022 Dec 26, 2020 $652.34M Feb 22, 2023
FY2021 Dec 28, 2019 $605.37M Feb 16, 2022
FY2020 Dec 29, 2018 $567.81M Feb 17, 2021
FY2019 Dec 30, 2017 $511.63M Feb 19, 2020
FY2018 Dec 31, 2016 $467.96M Feb 20, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.25B Feb 18, 2026
FY2025 Dec 28, 2024 $1.11B Feb 18, 2026
FY2025 Dec 30, 2023 $1.01B Feb 18, 2026
FY2024 Dec 31, 2022 $944.00M Feb 19, 2025
FY2023 Dec 25, 2021 $721.26M Feb 21, 2024
FY2022 Dec 26, 2020 $623.59M Feb 22, 2023
FY2021 Dec 28, 2019 $518.57M Feb 16, 2022
FY2020 Dec 29, 2018 $478.18M Feb 17, 2021
FY2019 Dec 30, 2017 $437.98M Feb 19, 2020
FY2018 Dec 31, 2016 $410.56M Feb 20, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $1.63B Feb 18, 2026
FY2025 Dec 28, 2024 $1.43B Feb 18, 2026
FY2025 Dec 30, 2023 $1.38B Feb 18, 2026
FY2024 Dec 31, 2022 $788.26M Feb 19, 2025
FY2023 Dec 25, 2021 $1.01B Feb 21, 2024
FY2022 Dec 26, 2020 $1.14B Feb 22, 2023
FY2021 Dec 28, 2019 $698.55M Feb 16, 2022
FY2020 Dec 29, 2018 $919.52M Feb 17, 2021
FY2019 Dec 30, 2017 $660.84M Feb 19, 2020
FY2018 Dec 31, 2016 $705.68M Feb 20, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $270.45M Feb 18, 2026
FY2025 Dec 28, 2024 $193.57M Feb 18, 2026
FY2025 Dec 30, 2023 $193.52M Feb 18, 2026
FY2024 Dec 31, 2022 $244.29M Feb 19, 2025
FY2023 Dec 25, 2021 $307.65M Feb 21, 2024
FY2022 Dec 26, 2020 $185.40M Feb 22, 2023
FY2021 Dec 28, 2019 $118.03M Feb 16, 2022
FY2020 Dec 29, 2018 $155.76M Feb 17, 2021
FY2019 Dec 30, 2017 $139.70M Feb 19, 2020
FY2018 Dec 31, 2016 $90.96M Feb 20, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $10.99B Feb 18, 2026
FY2025 Dec 28, 2024 $9.63B Feb 18, 2026
FY2024 Dec 30, 2023 $8.60B Feb 19, 2025
FY2023 Dec 31, 2022 $7.73B Feb 21, 2024
FY2022 Dec 25, 2021 $7.85B Feb 22, 2023
FY2021 Dec 26, 2020 $7.03B Feb 16, 2022
FY2020 Dec 28, 2019 $6.17B Feb 17, 2021
FY2019 Dec 29, 2018 $5.38B Feb 19, 2020
FY2018 Dec 30, 2017 $4.95B Feb 20, 2019
FY2017 Dec 31, 2016 $4.53B Feb 21, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $8.97B Feb 18, 2026
FY2025 Dec 28, 2024 $7.85B Feb 18, 2026
FY2025 Dec 30, 2023 $7.01B Feb 18, 2026
FY2025 Dec 31, 2022 $6.20B Feb 18, 2026
FY2024 Dec 25, 2021 $6.11B Feb 19, 2025
FY2023 Dec 26, 2020 $5.52B Feb 21, 2024
FY2022 Dec 28, 2019 $4.79B Feb 22, 2023
FY2021 Dec 29, 2018 $4.16B Feb 16, 2022
FY2020 Dec 30, 2017 $3.85B Feb 17, 2021
FY2019 Dec 31, 2016 $3.45B Feb 19, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $760.24M Feb 18, 2026
FY2025 Dec 28, 2024 $603.95M Feb 18, 2026
FY2025 Dec 30, 2023 $608.47M Feb 18, 2026
FY2024 Dec 31, 2022 $567.99M Feb 19, 2025
FY2023 Dec 25, 2021 $575.08M Feb 21, 2024
FY2022 Dec 26, 2020 $584.21M Feb 22, 2023
FY2021 Dec 28, 2019 $467.11M Feb 16, 2022
FY2020 Dec 29, 2018 $301.02M Feb 17, 2021
FY2019 Dec 30, 2017 $286.98M Feb 19, 2020
FY2018 Dec 31, 2016 $224.55M Feb 20, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $6.97B Feb 18, 2026
FY2025 Dec 28, 2024 $6.00B Feb 18, 2026
FY2024 Dec 30, 2023 $5.26B Feb 19, 2025
FY2023 Dec 31, 2022 $4.73B Feb 21, 2024
FY2022 Dec 25, 2021 $4.32B Feb 22, 2023
FY2021 Dec 26, 2020 $3.75B Feb 16, 2022
FY2020 Dec 28, 2019 $3.23B Feb 17, 2021
FY2019 Dec 29, 2018 $2.71B Feb 19, 2020
FY2018 Dec 30, 2017 $2.42B Feb 20, 2019
FY2017 Dec 31, 2016 $2.06B Feb 21, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $2.28B Feb 18, 2026
FY2025 Dec 28, 2024 $2.08B Feb 18, 2026
FY2024 Dec 30, 2023 $1.69B Feb 19, 2025
FY2023 Dec 31, 2022 $1.28B Feb 21, 2024
FY2022 Dec 25, 2021 $1.50B Feb 22, 2023
FY2021 Dec 26, 2020 $1.46B Feb 16, 2022
FY2020 Dec 28, 2019 $1.03B Feb 17, 2021
FY2019 Dec 29, 2018 $1.20B Feb 19, 2020
FY2018 Dec 30, 2017 $891.49M Feb 20, 2019
FY2017 Dec 31, 2016 $846.88M Feb 21, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 8 Feb 18, 2026
FY2025 Dec 28, 2024 7 Feb 18, 2026
FY2025 Dec 30, 2023 6 Feb 18, 2026
FY2024 Dec 31, 2022 5 Feb 19, 2025
FY2023 Dec 25, 2021 5 Feb 21, 2024
FY2020 Dec 26, 2020 1 Feb 17, 2021
FY2020 Sep 26, 2020 1 Feb 17, 2021
FY2020 Jun 27, 2020 0 Feb 17, 2021
FY2020 Mar 28, 2020 0 Feb 17, 2021
FY2020 Dec 28, 2019 1 Feb 17, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 8 Feb 18, 2026
FY2025 Dec 28, 2024 7 Feb 18, 2026
FY2025 Dec 30, 2023 6 Feb 18, 2026
FY2024 Dec 31, 2022 5 Feb 19, 2025
FY2023 Dec 25, 2021 5 Feb 21, 2024
FY2020 Dec 26, 2020 1 Feb 17, 2021
FY2020 Sep 26, 2020 1 Feb 17, 2021
FY2020 Jun 27, 2020 0 Feb 17, 2021
FY2020 Mar 28, 2020 0 Feb 17, 2021
FY2020 Dec 28, 2019 1 Feb 17, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 192.62M Feb 18, 2026
FY2025 Dec 28, 2024 192.47M Feb 18, 2026
FY2024 Dec 30, 2023 191.78M Feb 19, 2025
FY2023 Dec 31, 2022 191.62M Feb 21, 2024
FY2022 Dec 25, 2021 192.61M Feb 22, 2023
FY2021 Dec 26, 2020 191.57M Feb 16, 2022
FY2020 Dec 28, 2019 190.69M Feb 17, 2021
FY2019 Dec 29, 2018 189.46M Feb 19, 2020
FY2018 Dec 30, 2017 188,189 Feb 20, 2019
FY2017 Dec 31, 2016 188,565 Feb 21, 2018